146 related articles for article (PubMed ID: 20649763)
1. Association between indoxyl sulfate and skeletal resistance in hemodialysis patients.
Goto S; Fujii H; Hamada Y; Yoshiya K; Fukagawa M
Ther Apher Dial; 2010 Aug; 14(4):417-23. PubMed ID: 20649763
[TBL] [Abstract][Full Text] [Related]
2. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients.
Fujimori A; Okada S; Sakai M; Tome K; Fukagawa M
Nephron Clin Pract; 2011; 118(4):c375-9. PubMed ID: 21325869
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
4. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
[TBL] [Abstract][Full Text] [Related]
5. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
6. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
[TBL] [Abstract][Full Text] [Related]
7. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
[TBL] [Abstract][Full Text] [Related]
8. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
9. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
Nagata Y; Inaba M; Imanishi Y; Okazaki H; Yamada S; Mori K; Shoji S; Koyama H; Okuno S
Osteoporos Int; 2015 Mar; 26(3):1053-61. PubMed ID: 25403902
[TBL] [Abstract][Full Text] [Related]
10. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
[TBL] [Abstract][Full Text] [Related]
11. Effects of Lowering Dialysate Calcium Concentration on Bone Metabolic Markers in Hemodialysis Patients With Suppressed Serum Parathyroid Hormone: A Preliminary Study.
Niwa H; Fukasawa H; Ishibuchi K; Kaneko M; Yasuda H; Furuya R
Ther Apher Dial; 2018 Oct; 22(5):503-508. PubMed ID: 29923680
[TBL] [Abstract][Full Text] [Related]
12. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
14. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
Nowak Z; Konieczna M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
[TBL] [Abstract][Full Text] [Related]
15. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
Janckila AJ; Lederer ED; Price BA; Yam LT
Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
[TBL] [Abstract][Full Text] [Related]
17. Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients.
Nakashima A; Yorioka N; Mizutani T; Yamagata Z; Ueno T; Takasugi N
Nephron Clin Pract; 2005; 99(3):c78-85. PubMed ID: 15665550
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of bone resorption markers in hemodialysis patients.
Hamano T; Tomida K; Mikami S; Matsui I; Fujii N; Imai E; Rakugi H; Isaka Y
Bone; 2009 Jul; 45 Suppl 1():S19-25. PubMed ID: 19332165
[TBL] [Abstract][Full Text] [Related]
19. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.
Chu P; Chao TY; Lin YF; Janckila AJ; Yam LT
Am J Kidney Dis; 2003 May; 41(5):1052-9. PubMed ID: 12722040
[TBL] [Abstract][Full Text] [Related]
20. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients.
Taki K; Tsuruta Y; Niwa T
Am J Nephrol; 2007; 27(1):30-5. PubMed ID: 17215572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
